We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

DEA Finalizes Prescription Opioid Anti-Diversion Policy

Law360 (July 11, 2018, 8:46 PM EDT) -- The U.S. Drug Enforcement Administration finalized plans Wednesday to scrutinize diversion of prescription opioids for illicit uses when setting limits on opioid production, shooting down industry objections about potential shortages and methods of assessing diversion.

The DEA’s final rule was virtually identical to a proposed rule issued in April. It will formalize the agency's unofficial practice of examining how well drugmakers monitor suspicious opioid orders, and will thereby "encourage vigilance on the part of opioid manufacturers," according to a government announcement on Wednesday.

If drugmakers perform...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.